KRAS and neoplasm: Although these isolated findings suggest the potential of TCR-engineered T cells targeting KRAS G12D mutations to mediate tumor regression in PDAC, the lack of reproducibility underscores the need for further trials to identify reliable indicators and optimize patient selection for this type of cellular therapy.